UnitedHealth's $112 Billion Safety Net: Do Optum and Medicare Advantage Make UNH Still Pricey?

Operating recovery is real, but the legal overhang still matters

UnitedHealth's latest recovery has weakened the simplest bear case: that the company is still operationally broken. In the most recent quarter, it generated $112.0 billion in revenue, posted adjusted EPS of $6.38 versus $4.08 a year earlier, and lifted operating earnings 55%. That looks less like a company merely surviving a headline cycle and more like one restoring basic discipline.

The valuation-relevant point is that this turnaround is no longer purely theoretical. Management has re-established full-year guidance of at least $16.00 in adjusted EPS on $445.5 billion to $448.0 billion of revenue. Investors who treated UNH as a "show me" story could not easily dismiss that anymore.

But better operations have not ended the scrutiny. UnitedHealth says it began complying with formal criminal and civil requests from the Department of Justice and is conducting third-party reviews of coding, managed care practices, and pharmacy processes. Compliance is not clearance, and that distinction still matters for valuation.

That helps explain why UNH can still look expensive on the surface. The market appears to be pricing in strong execution while still demanding a discount for legal risk. If guidance holds and scrutiny stays contained, that gap can narrow quickly. If the government net keeps widening, the multiple likely stays capped.

Optum and Medicare Advantage are the cushion, and the debate

That operating recovery matters because it is coming from the parts of the business investors still trust. Medicare Advantage and Optum Health helped drive the quarter's beat, while commercial benefits remained pressured by elevated cost trends. The cushion is real; so is the reason some investors still hesitate.

Why the cushion matters

The market is not really debating whether UnitedHealth can produce earnings. It is debating how durable those earnings are when one part of the business strengthens while regulators keep looking elsewhere. That is where Optum and Medicare Advantage become both valuable and controversial.

Management has re-established its full-year outlook at $445.5 billion to $448.0 billion of revenue and at least $16.00 in adjusted EPS. That does not prove the legal overhang is gone, but it does show that UnitedHealth's core engines are strong enough to support a consolidation story, not just a survival story.

Why hesitation persists

The hesitation is not just fearmongering. A recent report said the DOJ investigation extends beyond Medicare Advantage, also touching billing practices at Optum Rx and how UnitedHealth reimburses its own physicians. At the same time, UnitedHealth has said it has begun complying with formal criminal and civil requests and is running third-party reviews of coding, managed care, and pharmacy processes.

That tension is why the stock can look expensive and still trade as if some risk remains unpriced. Better execution does not automatically equal regulatory clearance.

The Amedisys case and the broader antitrust question

Some of the hesitation also comes from the fact that the government is not only investigating; it is also acting. In the Amedisys matter, the proposed settlement would require divestiture of at least 164 home health and hospice facilities and a $1.1 million civil penalty. That suggests the government sees real competitive and compliance concerns in parts of UnitedHealth's home-health buildout, even in a resolved case.

There is another layer of scrutiny as well. Reports say DOJ is examining Optum's acquisition of doctor's offices, adding an antitrust horizon beyond the immediate billing questions.

Valuation depends on what the market is asking you to assume

The core valuation question is not whether UnitedHealth can earn well again. It already has, with a strong recent quarter and re-established full-year outlook. The question is what assumptions the market is asking you to accept in order to pay a premium today.

For UNH to justify a richer multiple than a more constrained insurer or services business, investors effectively have to assume that operating repair will continue while legal scrutiny becomes less disruptive over time. That is a reasonable starting point, but it is not the same as saying the overhang has disappeared.

Where recency bias can creep in

Investors who see restored guidance can start treating evidence of repair as evidence of clearance. The evidence of repair is real. The evidence of clearance is not.

Bears will argue the scrutiny is widening, not narrowing. A recent report said the DOJ inquiry extends beyond Medicare Advantage. Separately, the proposed Amedisys settlement requires divestiture of at least 164 facilities. That is real pressure.

Bulls, though, have a credible rebuttal: containment is not the same as collapse. UnitedHealth says it has begun complying with formal criminal and civil requests and is running third-party reviews of coding, managed care, and pharmacy processes. For now, the debate is about future constraint, not present malfunction.

What could move the stock price from here

The key signal is simple: if fresh legal headlines arrive before operations fully re-rate, the multiple can compress even if the numbers stay solid. A premium can hold only if execution remains strong while the legal overhang stays manageable.

Watch three things closely: - whether Medicare Advantage and Optum Health keep absorbing operating discipline without slipping back - whether guidance remains credible as care costs and compliance efforts continue - whether DOJ scrutiny stays contained or keeps spreading to new parts of the business